


Amendments to the Claims:

The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1.- 53. (Cancelled)

54. (Currently Amended) A method of treating an individual having a ~~condition~~ Alzheimer's disease, comprising the step of administering to ~~[[an]]the~~ individual a carbamoyl ester, wherein the carbamoyl ester ~~is selected from the group consisting of~~ has the formula:



wherein

~~R₁ and R₂ are each, independently or in combination,~~ is selected from the group consisting of a hydrogen, an unsubstituted alkyl, a substituted alkyl, an unsubstituted aralkyl, a substituted aralkyl, an unsubstituted heteroalkyl, a substituted heteroalkyl, an unsubstituted heteroaralkyl, a substituted heteroaralkyl, an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl, a substituted heteroaryl, an unsubstituted cycloalkyl, a

substituted cycloalkyl, an unsubstituted heterocycloalkyl and a substituted heterocycloalkyl;

R₂ is selected from the group consisting of an unsubstituted aralkyl and a substituted aralkyl, wherein said aralkyl group is an aryl substituent linked by a branched alkyl group having from 3-5 carbon atoms; and

R₃, R₄, and R₅ are each, independently ~~or in combination~~, selected from the group consisting of a hydrogen, an unsubstituted alkyl, a substituted alkyl, an unsubstituted aralkyl, a substituted aralkyl, an unsubstituted heteroalkyl, a substituted heteroalkyl, an unsubstituted heteroaralkyl, a substituted heteroaralkyl, an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl, a substituted heteroaryl, an unsubstituted cycloalkyl, a substituted cycloalkyl, an unsubstituted heterocycloalkyl and a substituted heterocycloalkyl; ~~and~~

~~further wherein the condition is selected from a central nervous system condition, a peripheral nervous system condition and an autonomic nervous system condition.~~

55. (Canceled)

56. (Canceled)


57. (Canceled)

58. (Previously Presented) The method of claim 54, wherein at least one of R₃, R₄, and R₅ is unsubstituted alkyl.


59. (Currently Amended) The method of claim 54, wherein ~~one of R₁ or R₂ is selected from the group consisting of H, substituted alkyl, and unsubstituted alkyl and the remaining R₁ or R₂ is selected from the group consisting of substituted aralkyl and unsubstituted aralkyl.~~

60. (Currently Amended) The method of claim 59, wherein ~~one of R₁ or R₂ is unsubstituted alkyl and the remaining R₁ or R₂ is substituted aralkyl.~~


61. (Previously Presented) The method of claim 54, wherein the carbamoyl ester is



62. (Previously Presented) The method of claim 61, wherein the carbamoyl ester is




63. (Currently Amended) The method of claim [[62]]61, wherein the carbamoyl ester




3


is selected from the group consisting of:




5




7




9




11




16



21




18



20

and

64. (Previously Presented) The method of claim 63, wherein the carbamoyl ester is



7

65. (Previously Presented) The method of claim 54, wherein the individual is a human.

66.-80. (Canceled)

81. (New) The method of claim 54, wherein R₂ is an unsubstituted aralkyl group, wherein said aralkyl group is an aryl substituent linked by a branched alkyl group having 3 carbon atoms.

82. (New) The method of claim 54, wherein R₂ is an unsubstituted aralkyl group, wherein said aryl group is phenyl.